Pharmacotherapy for pediatric and adolescent agitation in an inpatient behavioral health unit
Open Access
- 1 June 2026
- journal article
- Published by American Association of Psychiatric Pharmacists (AAPP) in Mental Health Clinician
- Vol. 16 (3) , 135-140
Abstract
Introduction: Pro re nata (PRN) medications can be administered for the treatment of agitation. Evidence-based recommendations for the pharmacologic treatment of agitation in children and adolescents admitted to a behavioral health unit are limited. The primary objective of this study was to analyze medication use patterns for managing agitation in a pediatric and adolescent inpatient behavioral health unit. The secondary objective was to evaluate the effectiveness and safety of commonly administered PRN medications in this population. Methods: This retrospective chart review included patients who received a 1-time or PRN medication for agitation while admitted to a pediatric and adolescent behavioral health unit between July 1, 2020, and June 31, 2022. Primary outcomes examined agents administered and the route and rate of concurrent medication administration. Secondary outcomes included administration of subsequent medications, the use of restraint or seclusion as a surrogate marker for effectiveness, and rate of adverse events for safety. Results: A total of 191 patients were included in the final analysis. There were 1238 doses of 1-time or PRN medication administered for agitation during the study period. Antipsychotics were administered most frequently (661, 53.4%). However, the most commonly administered medications were diphenhydramine (327, 26.4%), lorazepam (235, 19%), and olanzapine (224, 18.1%). Antipsychotic-induced extrapyramidal symptoms (EPS) occurred in 3 instances (0.24%), with all being managed with diphenhydramine. Discussion: When treating agitation in pediatric and adolescent patients admitted to an inpatient behavioral health unit, antipsychotics were administered most frequently. It appears that most doses were well tolerated, except for EPS in a subset of patients.Keywords
This publication has 10 references indexed in Scilit:
- Clinical pathway development to standardize pharmacological medication management of agitation in pediatric inpatient settings2024
- The agitated pediatric patient located in the emergency department: The APPLIED observational studyJACEP Open, 2022
- Efficacy of Combination Haloperidol, Lorazepam, and Diphenhydramine vs. Combination Haloperidol and Lorazepam in the Treatment of Acute Agitation: A Multicenter Retrospective Cohort StudyThe Journal of Emergency Medicine, 2022
- Management of Acute Agitation and Aggression in Children and Adolescents with Pro Re Nata Oral Immediate Release Antipsychotics in the Pediatric Emergency DepartmentJournal of Child and Adolescent Psychopharmacology, 2020
- Pro Re Nata Medication Use in Acute Care Adolescent Psychiatric UnitJournal of Child and Adolescent Psychopharmacology, 2020
- Best Practices for Evaluation and Treatment of Agitated Children and Adolescents (BETA) in the Emergency Department: Consensus Statement of the American Association for Emergency PsychiatryWestern Journal of Emergency Medicine, 2019
- Pharmacologic Management of Agitation and Aggression in a Pediatric Emergency Department – A Retrospective Cohort StudyThe Journal of Pediatric Pharmacology and Therapeutics, 2018
- Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and AdolescentsPediatrics, 2017
- Restraint Use for Psychiatric Patients in the Pediatric Emergency DepartmentPediatric Emergency Care, 2006
- Temperature measurement in paediatricsPaediatrics & Child Health, 2000